Creso Pharma

Creso Pharma is an Australian pharmaceutical company developing a portfolio of cannabis-derived therapeutics, nutraceutical, and lifestyle products for human and animal health. The company entered the psychedelic space in July 2021 upon completion of its acquisition of the Canadian psychedelic company Halucenex Life Sciences Inc.

In conjunction with the acquisition, Creso gained access to Halucenex’s pipeline of novel psychedelic molecules for post-traumatic stress disorder (PTSD), treatment-resistant depression (TRD), and other mental health conditions. Phase 2 clinical trials on psilocybin to treat TRD are also underway by the subsidiary, which will commence once it obtains the Dealer’s License from Health Canada. It also focuses on its comprehensive psilocybin and psychedelic-assisted psychotherapy which is performed in its medical facility in Nova Scotia equipped with six treatment rooms and a secure clinical research laboratory.

Creso has been listed on the Australian Securities Exchange (ASX) since 2016 and, following the acquisition of Halucenex, became the first fully-owned psychedelic medicines company to be listed on ASX. It also dual-listed on the over-the-counter (OTCQB) markets in June 2021 under the ticker symbol “COPHF”. It also intends to list on Nasdaq, following the termination of a proposed merger agreement with Ontario-based magic truffles company Red Light Holland, in August 2021.